When was Servier Pharmaceuticals founded?

Servier Pharmaceuticals was founded in 1954.

Where is Servier Pharmaceuticals located?

Servier Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts.

How many employees does Servier Pharmaceuticals have?

As of Apr 30, 2026, the latest employee count at Servier Pharmaceuticals is 948.

Is Servier Pharmaceuticals a funded company?

Servier Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Servier Pharmaceuticals rank among its competitors?

Servier Pharmaceuticals ranks 30th amongst 94 active competitors, of which 31 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Orca Bio, which secured $250M in Jan, 2026.

Who are the top competitors of Servier Pharmaceuticals?

Servier Pharmaceuticals' top competitors include MaaT Pharma, Ossium Health and Ajax. Among them, Orca Bio secured the most recent funding round in January, 2026.

Servier Pharmaceuticals - 2026 Company Profile & Competitors

Servier Pharmaceuticals is an unfunded company based in Boston (United States), founded in 1954. It operates as a Provider of therapeutics for cancer. Servier Pharmaceuticals has not raised any funding yet. The company has 94 active competitors, including 31 funded and 22 that have exited. Its top competitors include companies like MaaT Pharma, Ossium Health and Ajax.

Company Details

Servier Pharmaceuticals provide therapeutics for cancer. The company's lead candidate, Oncaspar, is a cancer medicine used in adults and children to treat acute lymphoblastic leukemia (ALL), a cancer of white blood cells called lymphoblasts. The candidate contains the active substance pegaspargase, which is a modified enzyme used as an antineoplastic agent.

Website: servier.us
Social
Phone Number: +1 **********
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

1954

Location

Boston, United States

Stage

Unfunded

Ranked

30^th among 94 active competitors

Employee Count

948 as on Apr 30, 2026

Similar Companies

MaaT Pharma & 97 more

View Servier Pharmaceuticals' full profile

Servier Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Servier Pharmaceuticals Llc CIN: 371897970 , United States, Active	Dec 26, 999	-	495 (As on Dec 31, 2024)	-

Servier Pharmaceuticals has not raised any funding rounds yet.

Servier Pharmaceuticals' employee count trend

Servier Pharmaceuticals has 948 employees as of Apr 26. Here is Servier Pharmaceuticals's employee count trend over the years:

Employee count trend for Servier Pharmaceuticals

Uncover Servier Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Servier Pharmaceuticals include MaaT Pharma, Ossium Health and Ajax. Here is the list of Top 10 competitors of Servier Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Symbiosis, Credit Mutuel Equity & 11 others	66/100
2nd	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	CPMG, Vivo Capital & 12 others	65/100
3rd	Ajax 2019, Cambridge (United States), Acquired	Developer of targeted therapies for the treatment of hematologic malignancies	$135M	EcoR1, Goldman Sachs Asset Management & 8 others	64/100
4th	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MPM Capital, MidCap Financial & 6 others	64/100
5th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 10 others	63/100
6th	Auron Therapeutics 2018, Wellesley (United States), Series B	Developer of cancer therapeutics for the treatment of blood cancer	$118M	Mubadala, Qiming & 11 others	62/100
7th	Adicet Bio 2014, Menlo Park (United States), Public	Developer of immune cell therapeutic solutions for the treatment of cancer	$51M	Consensus Business Group, Orbimed & 18 others	61/100
8th	Priothera 2020, Dublin (Ireland), Series A	Developer of therapeutics for the treatment of hematological malignancies	$35.5M	Healthcap, Fountain Healthcare Partners & 4 others	59/100
9th	StemlineTherapeutics 2003, New York City (United States), Acquired	Oncology therapeutics innovator focused on transforming cancer patient lives	$15.1M	Avoro Capital, Great Point Partners & 1 others	58/100
10th	CERo Therapeutics 2016, San Francisco (United States), Public	Developer of platforms for cellular immunotherapy	$54.8M	Arch Venture Partners, Altitude Life Science Ventures ... Read more	57/100
30th	Servier Pharmaceuticals 1954, Boston (United States), Unfunded	Provider of therapeutics for cancer	-	-	46/100